Literature DB >> 7987388

Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.

A Kamb1, D Shattuck-Eidens, R Eeles, Q Liu, N A Gruis, W Ding, C Hussey, T Tran, Y Miki, J Weaver-Feldhaus.   

Abstract

A locus for familial melanoma, MLM, has been mapped within the same interval on chromosome 9p21 as the gene for a putative cell cycle regulator, p16INK4 (CDKN2) MTS1. This gene is homozygously deleted from many tumour cell lines including melanomas, suggesting that CDKN2 is a good candidate for MLM. We have analysed CDKN2 coding sequences in pedigrees segregating 9p melanoma susceptibility and 38 other melanoma-prone families. In only two families were potential predisposing mutations identified. No evidence was found for heterozygous deletions of CDKN2 in the germline of melanoma-prone individuals. The low frequency of potential predisposing mutations detected suggests that either the majority of mutations fall outside the CDKN2 coding sequence or that CDKN2 is not MLM.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987388     DOI: 10.1038/ng0994-22

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  149 in total

1.  A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.

Authors:  P Ciotti; J P Struewing; M Mantelli; A Chompret; M F Avril; P L Santi; M A Tucker; G Bianchi-Scarrà; B Bressac-de Paillerets; A M Goldstein
Journal:  Am J Hum Genet       Date:  2000-06-22       Impact factor: 11.025

Review 2.  Cell cycle checkpoints and their inactivation in human cancer.

Authors:  M Molinari
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

3.  Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma.

Authors:  P A van der Velden; L A Sandkuijl; W Bergman; S Pavel; L van Mourik; R R Frants; N A Gruis
Journal:  Am J Hum Genet       Date:  2001-08-07       Impact factor: 11.025

Review 4.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

5.  Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway.

Authors:  Janet L Maldonado; Luika Timmerman; Jane Fridlyand; Boris C Bastian
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

Review 6.  Hereditary pancreatic cancer.

Authors:  Shilpa Grover; Sapna Syngal
Journal:  Gastroenterology       Date:  2010-08-19       Impact factor: 22.682

7.  Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis.

Authors:  Jia-Li Jiang; Gui-Lan Tian; Shu-Jiao Chen; L I Xu; Hui-Qin Wang
Journal:  Exp Ther Med       Date:  2015-07-24       Impact factor: 2.447

8.  Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis.

Authors:  T Tokino; T Urano; T Furuhata; M Matsushima; T Miyatsu; S Sasaki; Y Nakamura
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

9.  Perceived risk following melanoma genetic testing: a 2-year prospective study distinguishing subjective estimates from recall.

Authors:  Lisa G Aspinwall; Jennifer M Taber; Wendy Kohlmann; Samantha L Leaf; Sancy A Leachman
Journal:  J Genet Couns       Date:  2013-12-10       Impact factor: 2.537

10.  Genome-wide association studies in cancer--current and future directions.

Authors:  Charles C Chung; Wagner C S Magalhaes; Jesus Gonzalez-Bosquet; Stephen J Chanock
Journal:  Carcinogenesis       Date:  2009-11-11       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.